SSY GROUP (02005): Labetalol Hydrochloride Has Been Approved by the National Medical Products Administration for Registration as an Active Pharmaceutical Ingredient Used in Marketed Formulations

SSY GROUP (02005) announces that the group's Labetalol Hydrochloride has been approved by China's National Medical Products Administration for registration as an active pharmaceutical ingredient used in marketed formulations. Labetalol Hydrochloride is primarily used for the treatment of hypertension. The formulation of this product is a first-line emergency medication for hypertensive disorders of pregnancy. The group already holds the formulation approval for Labetalol Hydrochloride Injection. The approval of this API is an important implementation of the group's API-formulation integration strategy. Currently, the group's hypertension pipeline has established a complete product echelon covering conventional chronic disease oral monotherapy, fixed-dose combination formulations, hypertensive emergencies, and obstetric intravenous medications. Leveraging the dual-direction layout of APIs and formulations across multiple core antihypertensive varieties, the group continues to build an integrated industrial chain, comprehensively covering the rigid clinical needs of chronic hypertension management and emergency treatment, and consolidating its product competitive advantages in the cardiovascular field.